GoldenGolden

Efficacy

Able to finish something satisfactorly

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
AbbVie
June 2, 2021
www.prnewswire.com:443
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results of an analysis from the Phase 3 SELECT-PsA 2 clinical trial, showing that continuous treatment with...
AbbVie
June 2, 2021
www.prnewswire.com:443
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new analyses to be presented at the EULAR 2021 Virtual Congress showing patients with moderate to severe...
May 10, 2021
BioSpace
Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA - read this article along with other careers information, tips and advice on BioSpace
April 23, 2021
BioSpace
New Phase 3 Data Showed First-in-Class TREMFYA® (guselkumab) Provided Durable Complete Skin Clearance Through Five Years in Moderate to Severe Plaque Psoriasis (PsO) - read this article along with other careers information, tips and advice on BioSpace
April 20, 2021
Moneycontrol
Under the third phase of the vaccination drive commencing next month, manufacturers would be free to supply 50 percent doses to state governments as well as in the open market, for which they will have to make an advance declaration of the price, the government said in a statement.
April 8, 2021
clinicaltrials.gov
Clinical Trial to "Study the Efficacy and Therapeutic Safety of Ivermectin: (SAINTBO) - Full Text View.
March 25, 2021
clinicaltrials.gov
Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children <12 Years of Age - Full Text View.
April 1, 2021
clinicaltrials.gov
Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19 - Full Text View.
AbbVie Brasil
March 1, 2021
www.prnewswire.com:443
/PRNewswire/ -- A AbbVie (NYSE: ABBV) anuncia que a ANVISA - Agência Nacional de Vigilância Sanitária aprovou HUMIRA ® (adalimumabe) para o tratamento de...
Amgen
February 26, 2021
www.prnewswire.com:443
/PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive full results from the pivotal NAVIGATOR Phase 3 trial, which showed the potential...
AbbVie Brasil
February 5, 2021
www.prnewswire.com:443
/PRNewswire/ -- A AbbVie (NYSE: ABBV) anunciou (5/01/21) resultados positivos de dois estudos de Fase 3 em adultos com artrite psoriásica ativa, KEEPsAKE-1 e...
AbbVie Brasil
January 29, 2021
www.prnewswire.com:443
Uma proporção significativamente maior de pacientes com doença de Crohn tratados com qualquer uma das doses de risanquizumabe (600mg ou 1200mg) atingiu ambos...
AbbVie
January 25, 2021
www.prnewswire.com:443
/PRNewswire/ -- AbbVie (NYSE: ABBV), today announced that the European Commission (EC) has approved RINVOQTM (upadacitinib, 15 mg), an oral, once daily...
AbbVie Brasil
January 21, 2021
www.prnewswire.com:443
- Significativamente, mais pacientes adultos com retocolite ulcerativa grave, tratados com upadacitinibe, alcançaram remissão clínica (desfecho primário, pelo...
Tris Pharma, Inc.
January 20, 2021
www.prnewswire.com:443
/PRNewswire/ -- Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of...
AbbVie
January 7, 2021
www.prnewswire.com:443
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive results from two Phase 3 induction studies, ADVANCE and MOTIVATE, showing both doses of...
AbbVie
January 5, 2021
www.prnewswire.com:443
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from two Phase 3 studies in adults with active psoriatic arthritis, KEEPsAKE-1...
AbbVie
December 11, 2020
www.prnewswire.com:443
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP)...
AbbVie
December 10, 2020
www.prnewswire.com:443
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced top-line results from the Phase 3b Heads Up study showing that upadacitinib (30 mg, once daily) achieved...
December 9, 2020
clinicaltrials.gov
The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 - Full Text View.
SHOW MORE
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.